These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 25430674)
1. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach. Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674 [TBL] [Abstract][Full Text] [Related]
2. A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours. Shamash J; Powles T; Mutsvangwa K; Wilson P; Ansell W; Walsh E; Berney D; Stebbing J; Oliver T Ann Oncol; 2007 May; 18(5):925-30. PubMed ID: 17355956 [TBL] [Abstract][Full Text] [Related]
3. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363 [TBL] [Abstract][Full Text] [Related]
4. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study. Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084 [TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors. Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340 [TBL] [Abstract][Full Text] [Related]
6. Salvage combined chemotherapy with paclitaxel, ifosfamide and nedaplatin for patients with advanced germ cell tumors. Nakamura T; Ueda T; Oishi M; Nakanishi H; Fujihara A; Naya Y; Hongo F; Kamoi K; Okihara K; Miki T Int J Urol; 2015 Mar; 22(3):288-93. PubMed ID: 25393104 [TBL] [Abstract][Full Text] [Related]
7. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors. Farmakis D; Pectasides M; Pectasides D Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C; Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893 [TBL] [Abstract][Full Text] [Related]
9. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649 [TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer. Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526 [TBL] [Abstract][Full Text] [Related]
11. High-dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience. Richardson NH; Taza F; Abonour R; Althouse SK; Ashkar R; Abu Zaid M; Hanna NH; Kesler KA; Adra N; Einhorn LH Cancer; 2024 Sep; 130(18):3115-3122. PubMed ID: 38768296 [TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Economopoulos T; Raptis SA Eur Urol; 2004 Aug; 46(2):216-21. PubMed ID: 15245816 [TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy. Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group. Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830 [TBL] [Abstract][Full Text] [Related]
15. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. Hartmann JT; Einhorn L; Nichols CR; Droz JP; Horwich A; Gerl A; Fossa SD; Beyer J; Pont J; Schmoll HJ; Kanz L; Bokemeyer C J Clin Oncol; 2001 Mar; 19(6):1641-8. PubMed ID: 11250992 [TBL] [Abstract][Full Text] [Related]
16. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience. Yildiran Keskin GS; Erturk I; Aykan MB; Acar R; Dumludag A; Topal A; Koseoglu C; Kuzu OF; Ornek E; Karadurmus N Oncol Res Treat; 2024; 47(6):262-272. PubMed ID: 38583428 [TBL] [Abstract][Full Text] [Related]
17. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262 [TBL] [Abstract][Full Text] [Related]
18. Irinotecan and nedaplatin as salvage therapy for patients with advanced germ cell tumors following intensive treatment with cisplatin-based combination chemotherapies. Nishikawa M; Miyake H; Fujisawa M Int J Clin Oncol; 2016 Feb; 21(1):162-7. PubMed ID: 26123313 [TBL] [Abstract][Full Text] [Related]
19. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C; Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446 [TBL] [Abstract][Full Text] [Related]
20. Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Kollmannsberger C; Rick O; Klaproth H; Kubin T; Sayer HG; Hentrich M; Welslau M; Mayer F; Kuczyk M; Spott C; Kanz L; Bokemeyer C Br J Cancer; 2002 Sep; 87(7):729-32. PubMed ID: 12232755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]